BOSTON, MA, July 12, 2023 - ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will lead a panel discussion composed of industry experts on the key components of clinical trial management and data utilization.
The Clinical Operations in Oncology Trials East Coast Conference is focused on the clinical trial components and study management that are needed for successful performance. The conference will take place on July 11-12 in Burlington, Massachusetts.
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company's products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung, neuroendocrine, and pancreatic tumors. To learn more about Andarix, please visit www.andarix.com.
Contact Information
Chris Adams
Andarix
Boston, MA
United States
Voice: 6179579858
